Albert Oriol

Research interests

Publications

• Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2303379

• Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2204591

• Teclistamab in Relapsed or Refractory Multiple Myeloma

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2203478

• Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00592-4

• Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00128-5

• Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2024850

• Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00592-4

• Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30152-4

• Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

  The Lancet Haematology · 2019 · https://doi.org/10.1016/s2352-3026(19)30110-3

• Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

  The Lancet Haematology · 2019 · https://doi.org/10.1016/s2352-3026(19)30109-7

• Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

  The Lancet Haematology · 2019 · https://doi.org/10.1016/s2352-3026(19)30109-7

• Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.01231

• Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30578-8

• Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

  Leukemia · 2017 · https://doi.org/10.1038/leu.2017.138

• Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30632-5

• Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1607751

• Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

  The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(15)01120-4

• Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00464-7

• Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

  Blood · 2014 · https://doi.org/10.1182/blood-2014-01-550020

• Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1411321

• Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1402551

• Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2013 · https://doi.org/10.1016/s1470-2045(13)70380-2

• Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1300439

• Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2011.38.9429

• Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

  Blood · 2012 · https://doi.org/10.1182/blood-2012-02-408922

• High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

  Blood · 2011 · https://doi.org/10.1182/blood-2011-07-370460

• Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

  The Lancet Oncology · 2010 · https://doi.org/10.1016/s1470-2045(10)70187-x

• Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

  Blood · 2006 · https://doi.org/10.1182/blood-2006-04-019778

Current projects

No projects listed.